您现在的位置: 网站首页>慢病毒

慢病毒包装服务

现价1980元

  • 专业团队
  • 服务周到
  • 稳定可靠

产品详情

慢病毒产品感恩回馈,直击底价


Vpack慢病毒包装系统★

和元生物新升级的慢病毒包装系统,全面解决病毒不出毒和滴度低的问题,针对编码基因或非编码基因均有效提高滴度,平均滴度提高十倍以上。在此基础上改进的lncRNA慢病毒新包装系统,保证LncRNA表达更精准,载体荧光表达更亮,病毒出毒更稳定。
该包装系统已申请国家发明专利,获得授权。专利号为:ZL2020114185140

Vpack系统与常规病毒包装系统的比较如下:

                       
和元新升级lncRNA慢病毒包装系统与传统包装的方式比较如下:

                     

和元生物慢病毒系列产品:

定制病毒:涵盖过表达/干扰、CRISPR/Cas9、Cumate诱导表达系统、Tet-on/off系统、Cre-loxp系统。

现货慢病毒:涵盖CRISPR/Cas9敲除或激活文库、自噬单标或双标、荧光素酶现货、Cre/Flp重组酶、光遗传学等工具类现货。

慢病毒感染效果图:

慢病毒能够有效地感染培养的肝细胞、心肌细胞、神经元、内皮细胞、干细胞等多种类型的细胞。



不同培养体系对应细胞数、感染试剂用量及病毒量参考:



储存液浓度:Polybrene:1ug/μl,Polybrene-plus:100ug/μl

参考工作浓度:Polybrene:5μg/ml,Polybrene-plus:1μg/μl

※细胞数量为推荐铺板细胞数量,需根据细胞大小调整铺板数量(以感染时细胞密度30%为宜),按照实际感染时细胞数量去计算病毒加入量。

※为增加病毒与细胞接触的几率,可适当减少感染时培养基的体积。

感染复数(Multiplicity of Infection, MOI),含义为感染时病毒和细胞数量的比值,即平均每个细胞感染的病毒活性单位数(慢病毒单位为TU/cell)。


实验中按照设置好的MOI计算每孔需要加入的病毒量:
每孔加病毒量(μl)=MOI×感染时的细胞数/滴度(TU/ml)×1000。


客户使用和元慢病毒的文章列表 (部分)

[01]Cell.(IF=41.582). Xu M, Xu HH, Lin Yet al.LECT2,aligand for Tiel, plays a crucial role in liver fibrogenesis[J].2019,178(6):1478-1492.e20.[慢病毒,肝纤维化]

[02]Cell Metabolism.(IF=27.287).Lv H, Lv G, Chen C, et al. NAD+ metabolism maintains inducible PD-L1 expression to drive tumor immune evasion[J].2021,33(1):110-127.e5.[慢病毒过表达、干扰,肿瘤免疫,肝癌]

[03]Blood.(IF=22.113).Liu F. Gao Y. Xu B.et al. PEG10 amplification at 7a21.3 potentiates large-cell transformation in cutaneous T-cell lymphoma: PEG10 amplification potentiates LCT in CTCL[J].2021.[慢病毒干扰淋巴瘤]

[04]Nature cell biology.(IF=17.728).Shen SM, Zhang C, Ge MK, et al. PTENα and PTENβ promote carcinogenesis through WDR5 and H3K4 trimethylation[J].2019,21(11):1436-1448.[慢病毒过表达、Cas9/dCas9,甲基化肝癌]

[05]Journal of hematology&oncolog.(IF=17.388).Yang L, Chen Y, Liu N, et al. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N 6-methyladenosine of PARP1 mRNA and downregulating PTEN[J].2021,14(1)1-20.[慢病毒干扰,肾细胞癌]

[06]Autophagy.(IF=16.016).Wang B, Yin X, Gan W, et al.PRCC-TFE3 fusion-mediated PRKN/parkin-dependent mitophagy promotes cell survival and proliferation in PRCC-TFE3 translocation renalcellcarcinoma[Jl.Autophagy.[慢病毒过表达,肾细胞癌]

[07].Cell Death &Differentiation.(IF=15.828)Ji J, Ding K, Luo T, et al.TRIM22 activates NF-kB sienaling in glioblastoma by accelerating the degradation of lκBα[J].2021,28(1):367-381.[慢病毒 过表达、Cas9,胶质瘤]

[08]Cell Death &Differentiation.(IF=15.828).Hou Y, Zhang O, Pang W, et al.YTHDC1-medated augmentation of mir-30d in repressing pancreatic tumorigenesis via attenuation of RUNX1-induced transcriptional activation of Warburg effect[J].2021:1-20.[慢病毒过表达,肿瘤代谢,胰腺癌]

[09]Cell Death &Differentiation.(IF=15.828).Ji J, DingK, LuoT, et al.TRIM22 activates NF-κB signaling in glioblastoma by accelerating the degradation of lκBα[J].2021,28(1): 367-381.[慢病毒过表达、Cas9.信号通路,胶质瘤]

[10]Nature communications.(IF=14.919).Song H, Song J, Cheng M, et al.METTL3-mediated m6A RNA methylation promotes the anti-tumour immunity of natural killer cells[J]. 2021,12(1):1-15.[慢病毒干扰,肿瘤免疫,NK细胞,肝癌]

[11]Nature communications.(IF=14.919).Liu J, Liu ZX, Wu QN, et al.Long noncoding RNA AGPG regulates PFKFB3-mediated tumor glycolytic reprogramming[J].2020,11(1): 1-16.[慢病毒 过表达 干扰,糖酵解,食道鳞状细胞癌]

[12]Nature communications.(IF=14.919).Ge MK, Zhang N, Xia L, et al.FBX022 degrades nuclear PTEN to promote tumorienesis[J].2020,11(1):1-14.[慢病毒Cas9,结直肠癌]

[13]Nature communications.(IF=14.919).Zhane M, Yang W, Wang P, et al.CCL7 recruits cDC1 to promote antitumor immunity and facilitate checkpoint immunotherapy to non-small cell lung cancer[J].2020,11(1)1-17.[腺病毒-CRE]

[14]Nature communications.(IF=14.919).Yang Z, Xu G, Wane B, et al.UP12 downregulaion orchestrates a protumourigenic microenvironment and enhances lung tumour resistance to PD-1 blockade[J].2021,12(1):1-14.[慢病毒 过表达,腺病毒-crePD-1耐药]

[15]Nature Communications.(IF=14.919).Huang X, Pan L, Zuo Z, et al.LINC0082 inactivates transcription co-regulatorPGC-1α to promote pancreatic cancer malignancy through metabolic remodelling[J].2021,12(1):1-16[慢病毒Cas9,肿瘤代谢,胰腺癌]

[16] Nature communications.(IF=14.919).Wang Z, Wang F, Zhong J, et al.Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors[J].2020,11(1)1-13.[慢病毒 过表达,血管生产]

[17]Theranostics.(IF=11.556).Chen Y, Pan C, Wang X, et al.Silencing of METTL3 effectively hinders invasion and metastasis of prostate cancer cells[J].2021,11(16):7640.[慢病毒干扰,前列腺癌]

[18]Clinical and Translational Medicine(IF311.492).Wang C, Yang Z, Xu E, et al.Anolipoprotein C-Ⅱinduces EMT to promote gastric cancer peritoneal metastasis via PI3K/AKT/mTOR pathway[J].2021,11(8)e522.[慢病毒 过表达 干扰,胃癌]

[19]Molecular Therapy.(IF=11.454).Li R, Zeng L, Zhao H, et al.ATXN2-mediated translation of TNFR1 promotes esophageal squamous cell carcinoma via m6A-dependent manner[J].2022.[慢病毒过表达,食管鳞状细胞癌]

[20]Journal of Experimental &Clinical Cancer Research.(IF=11.161).Song C, Zhou C.HOXA10 mediates epithelial-mesenchymal transition to promote gastric cancer metastasis partly via modulation of TGFB2/Smad/METTL3 signaling axis[J].2021,40(1)1-16[慢病毒干扰、过表达,胃癌]

推荐载体列表(部分)


 

Copyright © 和元生物技术(上海)股份有限公司    地址:上海市浦东新区国际医学园区紫萍路908弄19号楼

点击询价